AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Restoring baseline levels of miR-320a can decelerate disease progression by inhibiting phosphorylation of the PI3K/AKT pathway, downstream of BCR::ABL1, hence diminishing the growth and survival of CML and enhancing the sensitivity of CML LSCs to IM [148].